Bristol Myers Squibb will invest approximately $2.3 billion to build a state-of-the-art manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs as the drugmaker expands its U.S. production capacity and prepares for the next generation of medicines.

 

The roughly 600,000-square-foot campus at Generation Park will be designed to grow and adapt for decades, with modular and multi-modal manufacturing capabilities that allow Bristol Myers Squibb to add or reconfigure capacity as its pipeline evolves.

 

The project marks a major step in BMS’ broader plan to invest $40 billion in the United States over five years across research and development, technology and domestic manufacturing.

 

From the outset, the Houston site will be capable of producing multiple types of medicines, including small molecules, biologics and antibody-drug conjugates. The facility will support drug-product and finished-goods manufacturing from late-stage development through commercial launch.

 

“This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Board Chair and CEO of Bristol Myers Squibb. 

 

“As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."

 

Texas officials also welcomed the investment, pointing to the state's growing life sciences sector and skilled workforce.

 

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” said Texas Governor Greg Abbott. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

 

US Commerce Secretary Howard Lutnick linked the project to the Trump administration's push to expand domestic pharmaceutical production.

 

"We are making pharmaceuticals in America again thanks to President Trump’s America First Trade Agenda,” said US Secretary of Commerce Howard Lutnick. “Bristol Myers Squibb’s $2.3 billion investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines.”

 

BMS said the Houston campus will be built around flexibility, allowing manufacturing capabilities to be brought online rapidly as commercial and pipeline requirements change.

 

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” said Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb. 

 

“This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

 

The Houston facility will feature architecture designed to accommodate future manufacturing technologies, digital integration and automation. BMS said the campus is intended to remain adaptable as capabilities and production needs change.

 

The company expects the site to expand in both scale and capability beyond its initial configuration, giving it the ability to respond to changes in its drug pipeline and commercial demand.

 

The Houston investment is part of BMS' broader effort to strengthen its domestic manufacturing footprint and reinforce U.S. pharmaceutical supply chains.

 

The company said the US biopharmaceutical industry conducts nearly $117 billion in research annually and employs more than 300,000 manufacturing workers. BMS invested approximately $10 billion in research and development in 2025, supporting the development of new medicines.

 

The industry directly employed more than one million U.S. workers in 2022 and, with an employment multiplier of 4.69, supported more than 3.8 million additional jobs, for a total employment impact of more than 4.9 million jobs across the U.S. economy, according to figures cited by BMS.

 

For Houston, the project brings hundreds of skilled jobs and a major new manufacturing investment. For BMS, it represents a bet on flexible, digitally enabled domestic production—and a manufacturing platform designed to keep pace with the company's pipeline for years to come.